Targets Rise

Roivant Sciences’ valuation model remains anchored at a $27.0 per‑share fair value, but the required return has risen to a discount rate of 7.54%, tightening the price target narrative. The shift follows the rescheduling of batoclimab Phase 3 readouts to 2026 and the persistence of litigation over Moderna royalties. Analysts such as Citi’s Samantha Semenkow and H.C. Wainwright’s Douglas Tsao have nevertheless lifted their price targets, pointing to Roivant’s clarified clinical timeline and improved investor communication as key upside drivers.